Details of the Drug

General Information of Drug (ID: DMOFIBM)

Drug Name
LMT-X
Synonyms Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Alzheimer disease 8A20 Phase 3 [2]
Cross-matching ID
TTD ID
D05XDZ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Inhibitor [3]
TAR DNA binding protein 43 (TARDBP) TT9RZ03 TADBP_HUMAN Inhibitor [4]
Tau protein aggregation (TauA) TTZGF8B NOUNIPROTAC Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Microtubule-associated protein tau (MAPT) DTT MAPT 3.76E-06 -0.22 -0.6
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
3 Clinical pipeline report, company report or official report of TauRx.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81.